182 related articles for article (PubMed ID: 34741723)
21. Effects of antiviral therapy on long-term outcome after liver resection for hepatitis B virus-related hepatocellular carcinoma.
Urata Y; Kubo S; Takemura S; Uenishi T; Kodai S; Shinkawa H; Sakae M; Kaneda K; Ohata K; Nozawa A; Suehiro S
J Hepatobiliary Pancreat Sci; 2012 Nov; 19(6):685-96. PubMed ID: 22203455
[TBL] [Abstract][Full Text] [Related]
22. Long-term outcomes and predictive scores for hepatocellular carcinoma and hepatitis B surface antigen seroclearance after hepatitis B e-antigen seroclearance.
Fung J; Cheung KS; Wong DK; Mak LY; To WP; Seto WK; Lai CL; Yuen MF
Hepatology; 2018 Aug; 68(2):462-472. PubMed ID: 29534307
[TBL] [Abstract][Full Text] [Related]
23. Patients with chronic hepatitis B treated with oral antiviral therapy retain a higher risk for HCC compared with patients with inactive stage disease.
Cho JY; Paik YH; Sohn W; Cho HC; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC
Gut; 2014 Dec; 63(12):1943-50. PubMed ID: 24615378
[TBL] [Abstract][Full Text] [Related]
24. Reassessing the accuracy of PAGE-B-related scores to predict hepatocellular carcinoma development in patients with chronic hepatitis B.
Yip TC; Wong GL; Wong VW; Tse YK; Liang LY; Hui VW; Lee HW; Lui GC; Chan HL
J Hepatol; 2020 May; 72(5):847-854. PubMed ID: 31857194
[TBL] [Abstract][Full Text] [Related]
25. [Risk analysis for hepatocellular carcinoma in patients with chronic hepatitis B-associated cirrhosis complicated by type 2 diabetes mellitus: a 5-year prospective cohort study].
Tang C; Hu C; Zhou Y; Song Y; Li M; Liao M; Sun J; Zhong C; Zhou L; Lin Z; Zhou Y
Nan Fang Yi Ke Da Xue Xue Bao; 2021 Mar; 41(3):313-318. PubMed ID: 33849820
[TBL] [Abstract][Full Text] [Related]
26. Antiviral therapy for chronic hepatitis B virus infection and development of hepatocellular carcinoma in a US population.
Gordon SC; Lamerato LE; Rupp LB; Li J; Holmberg SD; Moorman AC; Spradling PR; Teshale EH; Vijayadeva V; Boscarino JA; Henkle EM; Oja-Tebbe N; Lu M;
Clin Gastroenterol Hepatol; 2014 May; 12(5):885-93. PubMed ID: 24107395
[TBL] [Abstract][Full Text] [Related]
27. Moderate levels of serum hepatitis B virus DNA are associated with the highest risk of hepatocellular carcinoma in chronic hepatitis B patients.
Kim GA; Han S; Choi GH; Choi J; Lim YS
Aliment Pharmacol Ther; 2020 Jun; 51(11):1169-1179. PubMed ID: 32291781
[TBL] [Abstract][Full Text] [Related]
28. Effective viral suppression is necessary to reduce hepatocellular carcinoma development in cirrhotic patients with chronic hepatitis B: Results of a 10-year follow up.
Zhang W; Wang X; Wang Y; Zhao X; Duan W; Wang Q; Wu X; Kong Y; Ma H; You H; Ou X; Jia J
Medicine (Baltimore); 2017 Nov; 96(44):e8454. PubMed ID: 29095292
[TBL] [Abstract][Full Text] [Related]
29. Factors associated with persistent positive in HBV DNA level in patients with chronic Hepatitis B receiving entecavir treatment.
Li J; Dong XQ; Cao LH; Zhang ZQ; Zhao WF; Shang QH; Zhang DZ; Ma AL; Xie Q; Gui HL; Zhang G; Liu YX; Shang J; Xie SB; Liu YQ; Zhang C; Wang GQ; Zhao H;
Front Cell Infect Microbiol; 2023; 13():1151899. PubMed ID: 37396307
[TBL] [Abstract][Full Text] [Related]
30. Verification of hepatitis B-related hepatocellular carcinoma predictive models to evaluate the risk of HCC in patients with liver cirrhosis under antiviral treatment.
Huang X; Wang H; Zhang W; Gu E
Eur J Gastroenterol Hepatol; 2022 May; 34(5):546-552. PubMed ID: 35170528
[TBL] [Abstract][Full Text] [Related]
31. Hepatitis B virus-related hepatocellular carcinoma in the era of antiviral therapy: The emerging role of non-viral risk factors.
Li W; Deng R; Liu S; Wang K; Sun J
Liver Int; 2020 Oct; 40(10):2316-2325. PubMed ID: 32666675
[TBL] [Abstract][Full Text] [Related]
32. The risk of hepatocellular carcinoma within and beyond the first 5 years of entecavir in Korean patients with chronic hepatitis B.
Kim BG; Park NH; Lee SB; Jeon S; Park JH; Jung SW; Jeong ID; Bang SJ; Shin JW
Liver Int; 2018 Dec; 38(12):2269-2276. PubMed ID: 30052303
[TBL] [Abstract][Full Text] [Related]
33. Hepatitis B Virus Combo Mutations Improve the Prediction and Active Prophylaxis of Hepatocellular Carcinoma: A Clinic-Based Cohort Study.
Yin J; Wang J; Pu R; Xin H; Li Z; Han X; Ding Y; Du Y; Liu W; Deng Y; Ji X; Wu M; Yu M; Zhang H; Wang H; Thompson TC; Ni W; Cao G
Cancer Prev Res (Phila); 2015 Oct; 8(10):978-88. PubMed ID: 26290395
[TBL] [Abstract][Full Text] [Related]
34. Validation of the PAGE-B score to predict hepatocellular carcinoma risk in caucasian chronic hepatitis B patients on treatment.
Gokcen P; Guzelbulut F; Adali G; Degirmenci Salturk AG; Ozturk O; Bahadir O; Kanatsiz E; Kiyak M; Ozdil K; Doganay HL
World J Gastroenterol; 2022 Feb; 28(6):665-674. PubMed ID: 35317422
[TBL] [Abstract][Full Text] [Related]
35. Liver stiffness-based optimization of hepatocellular carcinoma risk score in patients with chronic hepatitis B.
Wong GL; Chan HL; Wong CK; Leung C; Chan CY; Ho PP; Chung VC; Chan ZC; Tse YK; Chim AM; Lau TK; Wong VW
J Hepatol; 2014 Feb; 60(2):339-45. PubMed ID: 24128413
[TBL] [Abstract][Full Text] [Related]
36. Performance of risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B) score in classifying treatment eligibility under 2012 Asian Pacific Association for the Study of the Liver (APASL) guideline for chronic hepatitis B patients.
Chen TM; Chang CC; Huang PT; Wen CF; Lin CC
Aliment Pharmacol Ther; 2013 Jan; 37(2):243-51. PubMed ID: 23171385
[TBL] [Abstract][Full Text] [Related]
37. Entecavir Reduced Serum Hepatitis B Core-Related Antigen in Chronic Hepatitis B Patients with Hepatocellular Carcinoma.
Mak LY; Ko KL; To WP; Wong DK; Seto WK; Fung J; Yuen MF
Gut Liver; 2020 Sep; 14(5):665-668. PubMed ID: 32457279
[TBL] [Abstract][Full Text] [Related]
38. Revised Korean Antiviral Guideline Reduces the Hepatitis B-related Hepatocellular Carcinoma Risk in Cirrhotic Patients.
Kim DS; Park SY; Kim BK; Park JY; Kim DY; Han KH; Lee YR; Tak WY; Kweon YO; Jung I; Han M; Kim EH; Ahn SH; Kim SU
J Korean Med Sci; 2021 Apr; 36(16):e105. PubMed ID: 33904261
[TBL] [Abstract][Full Text] [Related]
39. Serum fibrosis index-based risk score predicts hepatocellular carcinoma in untreated patients with chronic hepatitis B.
Liang LY; Lee HW; Wong VW; Yip TC; Tse YK; Hui VW; Lui GC; Chan HL; Wong GL
Clin Mol Hepatol; 2021 Jul; 27(3):499-509. PubMed ID: 33631920
[TBL] [Abstract][Full Text] [Related]
40. Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients.
Su TH; Hu TH; Chen CY; Huang YH; Chuang WL; Lin CC; Wang CC; Su WW; Chen MY; Peng CY; Chien RN; Huang YW; Wang HY; Lin CL; Yang SS; Chen TM; Mo LR; Hsu SJ; Tseng KC; Hsieh TY; Suk FM; Hu CT; Bair MJ; Liang CC; Lei YC; Tseng TC; Chen CL; Kao JH;
Liver Int; 2016 Dec; 36(12):1755-1764. PubMed ID: 27634134
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]